---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-004746"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2025-04-14T23:59:59+00:00"
generated_at: "2026-05-23T15:25:49.058709+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Coherus completes UDENYCA divestiture to Intas for $483.4M upfront; pivots to oncology

## Summary
- Closed sale of UDENYCA franchise on April 11, 2025; receives $483.4M cash including $118.4M for inventory.
- Eligible for two milestone payments up to $75M total if net sales thresholds met through 2027.
- Pro forma cash balance post-close ~$250M; cash runway extended over two years into 2027.
- Plans to use proceeds to repurchase $230M of 1.500% Convertible Notes due 2026.
- Focus shifts to LOQTORZI, casdozokitug, and CHS-114 novel oncology pipeline.

## SEC filing metadata
- accession: 0001558370-25-004746
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2025-04-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837025004746/0001558370-25-004746-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837025004746/chrs-20250411x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-004746
- JSON: https://secwatch.observer/filing/0001558370-25-004746.json
- Plain text: https://secwatch.observer/filing/0001558370-25-004746.txt

## Key facts
- M&A Transactions
  Coherus Oncology, Inc. completed a disposition involving Intas Pharmaceuticals Ltd. for $483.4 million in cash (closed 2025-04-11).
  - Action: disposition
  - Counterparty: Intas Pharmaceuticals Ltd.
  - Consideration: $483.4 million in cash
  - Closing: 2025-04-11
  source text: On April 11, 2025 (the “Closing Date”), the Company completed the divestiture of the Business (the “UDENYCA Disposition”) to Intas for upfront, all-cash consideration of $483.4 million in cash, inclusive of $118.4 million for UDENYCA product inventory.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837025004746/0001558370-25-004746-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.